| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement to Reviewers 2017
|
|
|
2018
|
117 |
C |
p. 50-52
|
artikel
|
| 2 |
Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium
|
Spigel, David R.
|
|
2018
|
117 |
C |
p. 38-43
|
artikel
|
| 3 |
A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer
|
Sculier, Jean-Paul
|
|
2018
|
117 |
C |
p. 32-37
|
artikel
|
| 4 |
Changing health care costs for NSCLC, what does it mean?
|
Postmus, Pieter E.
|
|
2018
|
117 |
C |
p. 62-63
|
artikel
|
| 5 |
Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
|
Zhang, Bo
|
|
2018
|
117 |
C |
p. 27-31
|
artikel
|
| 6 |
Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening
|
Yang, Wenjia
|
|
2018
|
117 |
C |
p. 20-26
|
artikel
|
| 7 |
Contents
|
|
|
2018
|
117 |
C |
p. v-vi
|
artikel
|
| 8 |
Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75]
|
Remon, J.
|
|
2018
|
117 |
C |
p. 80
|
artikel
|
| 9 |
Do we understage SABR candidates?
|
Crombag, Laurence M.M.J.
|
|
2018
|
117 |
C |
p. 60-61
|
artikel
|
| 10 |
Editorial Board
|
|
|
2018
|
117 |
C |
p. iii
|
artikel
|
| 11 |
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer
|
Ariyasu, Ryo
|
|
2018
|
117 |
C |
p. 1-6
|
artikel
|
| 12 |
Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy
|
Schonewolf, Caitlin A.
|
|
2018
|
117 |
C |
p. 53-59
|
artikel
|
| 13 |
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy
|
Grossi, Francesco
|
|
2018
|
117 |
C |
p. 64-69
|
artikel
|
| 14 |
Pulmonary aspergilloma mimicking synchronous lung cancer on PET/CT in a patient with head and neck cancer
|
Gorospe, Luis
|
|
2018
|
117 |
C |
p. 70-72
|
artikel
|
| 15 |
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
|
Gerber, David E.
|
|
2018
|
117 |
C |
p. 44-49
|
artikel
|
| 16 |
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort
|
Okamoto, Isamu
|
|
2018
|
117 |
C |
p. 14-19
|
artikel
|
| 17 |
Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer
|
Barua, Souptik
|
|
2018
|
117 |
C |
p. 73-79
|
artikel
|
| 18 |
Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy
|
Park, Byung Jo
|
|
2018
|
117 |
C |
p. 7-13
|
artikel
|
Tijdschrift beschrijving